Orthocell Secures Full Canadian Market Coverage for Remplir Nerve Repair Device

Orthocell has taken a major step in expanding its North American footprint, announcing the appointment of a second distributor in Canada for its flagship nerve repair product, Remplir. With this move, the company now has complete national coverage across the Canadian market, which is estimated to be worth 75 million US dollars.

The newly appointed distributor, based in Ontario, has secured exclusive rights to sell Remplir in eight provinces including Ontario, Quebec and Nova Scotia. This complements Orthocell’s existing distributor, which already covers Alberta and British Columbia, completing the company’s reach across both rural and urban centres nationwide.

This appointment follows a successful debut of Remplir at the American Society for Surgery of the Hand conference held in Vancouver in October. First Canadian sales are expected this quarter, marking an important commercial milestone.

Orthocell’s new Canadian partner brings deep expertise in the nerve, spine and orthopaedic implant sectors, backed by a team of 30 sales agents and six product managers. The team’s established networks are expected to accelerate adoption of Remplir in hospitals and clinics throughout the country.

The Canadian rollout will be overseen by Orthocell’s US-based marketing and medical education teams, leveraging the playbook used for the product’s US launch. This strategy is designed to deliver efficiencies and ensure consistency across North American operations.

Chief Executive Officer Paul Anderson said the appointment of the second distributor represents an important step forward in the company’s commercial strategy.

“We are very pleased to expand our Canadian distributor presence beyond Alberta and BC with this new appointment opening up the entire Canadian market,” Anderson said. “Each new distributor appointment is an important step, initiating targeted sales and marketing efforts in their territories and bringing us closer to generating new revenue streams.”

Remplir was granted a Canadian Medical Device Licence in April 2025, just two months after submission. This rapid regulatory turnaround allowed Orthocell to begin commercial planning earlier than expected.

Globally, Orthocell continues to build momentum with its distributor network. In addition to Canada, the company has established operations in 25 US states and made recent distributor appointments in Hong Kong. These complement existing long-term relationships in Australia and Singapore.

With over 50 million dollars in cash and no debt, Orthocell is well positioned to drive Remplir’s adoption and target a step change in revenue for the 2026 financial year. Momentum is also building in the much larger United States market, valued at 1.6 billion dollars, where the company is steadily gaining hospital approvals and onboarding surgeons.